Stryker hip implant lawsuits: how the LFIT V40 and Rejuvenate/ABG II litigation actually resolved and what's still pending

The Stryker hip implant litigation represents one of the most medical device mass torts resolved over the past decade, with two distinct federal Multidistrict Litigations addressing different product recalls. MDL 2441 (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation) in the U.S. District Court for the District of Minnesota before Senior Judge Donovan W. Frank addressed the July 2012 voluntary recall of Stryker's Rejuvenate and ABG II Modular Hip Systems. MDL 2768 (In re: Stryker LFIT Anatomic CoCr V40 Femoral Head Products Liability Litigation) in the U.S. District Court for the District of Massachusetts before Judge Indira Talwani addressed the September 2016 voluntary recall of the LFIT Anatomic CoCr V40 Femoral Head. The two MDLs operated in parallel: different products, different recall events, different procedural frameworks, but similar underlying allegations about metal-on-metal hip implant defects.

The theory in both litigations centers on the same fundamental defect mechanism: metal-on-metal hip implants released cobalt and chromium metal ions into surrounding tissue and the patient's bloodstream, causing metallosis (metal poisoning), pseudotumors, bone loss (osteolysis), chronic pain, and the need for revision surgery to remove and replace the failed implant. The metal-on-metal design produces friction between cobalt-chromium femoral head components and corresponding stem or acetabular components, generating microscopic metal debris that accumulates in surrounding tissue. The biological response includes inflammatory reaction, formation of fluid collections (pseudotumors), and progressive bone destruction. Affected patients typically experience pain at progressively higher levels, reduced mobility, and ultimately need for revision surgery to address the failing implant.

The resolution of these litigations occurred through two major settlements: the November 3, 2014 global settlement for the Rejuvenate and ABG II products at approximately $1.4 billion, providing a minimum award of $300,000 to most eligible victims (one of the largest minimum settlements in failed hip replacement litigation history); and a confidential $75 million settlement program covering approximately 2,500 claims by 500 plaintiffs for the LFIT V40 products. Both settlement programs included procedural framework for individual case evaluation, medical record review, and damage calculation. As of January 2026, MDL 2441 has approximately 16 pending cases remaining, while MDL 2768 has approximately 55-62 pending cases. Both MDLs continue accepting some new cases involving the LFIT V40 products, but the settlement framework has resolved the majority of cases. A separate emerging litigation involves the Tritanium Acetabular Shell, a newer Stryker hip implant component with similar alleged manufacturing defects.

This is how the Stryker hip implant litigation actually worked through its two parallel MDL structures, the theory of metal-on-metal hip implant failure, the procedural history of both recalls and settlements, the framework for current and prospective plaintiffs, and the strategic considerations for affected patients pursuing remaining claims.

What are the alleged defects in Stryker hip implants?

Stryker hip implants, including the Rejuvenate, ABG II, and LFIT V40 product lines, allegedly suffer from metal-on-metal design flaws at modular junctions and taper connections. These defects cause cobalt-chromium corrosion and fretting, releasing metal ions into surrounding tissue and the bloodstream, leading to metallosis, pseudotumors, bone loss, and revision surgery.

The femoral component. Replaces the upper part of the femur (thigh bone):

• Stem inserted into femoral canal
• Neck/taper component connecting to femoral head
• Often modular with multiple connection points

The femoral head. Ball component that replaces the natural femoral head:

• Articulates with the acetabular cup
• Typically made of cobalt-chromium, ceramic, or other materials

The acetabular component. Cup replacing the hip socket:

• Outer shell (often titanium or other metal)
• Inner liner (polyethylene, ceramic, or metal)
• Allows articulation with femoral head

The Stryker Rejuvenate Modular-Neck Hip Stem. Distinctive product features:

• Modular design with multiple components
• Cobalt-chromium modular neck component
• Modular junction between neck and stem
• Designed for hip replacement surgery

The Stryker ABG II Modular-Neck Hip Stem. Similar design:

The Stryker LFIT Anatomic CoCr V40 Femoral Head. Component used in various Stryker hip systems:

• Used with Accolade, Accolade 2, Citation, Meridian, Rejuvenate, and other stem systems
• Various sizes (36mm, 38mm, 40mm, 44mm primarily)

The alleged defect mechanism. Both product lines share similar defect theories:

Modular junction corrosion (Rejuvenate and ABG II). Where the modular neck meets the femoral stem:

• Friction and corrosion at junction
• Cobalt and chromium release from cobalt-chromium components

Trunnion failure (LFIT V40). Where the femoral head meets the femoral stem:

• Fretting corrosion at taper interface

• Mechanical disconnection in severe cases

• Adverse Local Tissue Reaction (ALTR)

• Aseptic Lymphocytic Vasculitis-Associated Lesion (ALVAL)

• Possible systemic toxicity from elevated metal levels

• Persistent or worsening hip pain (typically several years post-implant)

• Audible clicking, squeaking, or grinding

• Detection of elevated blood cobalt levels (>7 ppb concerning)

What injuries are alleged in Stryker hip implant lawsuits?

Plaintiffs in Stryker hip implant lawsuits allege metallosis from elevated cobalt and chromium levels, pseudotumor formation, bone destruction (osteolysis), adverse local tissue reactions, and the need for costly revision surgery. In severe cases, allegations include cardiomyopathy from systemic cobalt toxicity, permanent disability, and wrongful death.

Metallosis (metal poisoning). Elevated cobalt and chromium levels:

• Blood testing showing elevated metal ion levels
• Tissue testing showing metal deposits
• Systemic symptoms in severe cases
• Cardiomyopathy in rare severe cases
• Neurological symptoms in severe cases

Pseudotumors. Fluid-filled or solid masses developing around implant:

Aseptic Lymphocytic Vasculitis-Associated Lesion (ALVAL). Immune-mediated reaction:

Revision surgery requirement. Most affected patients required revision:

• Cost typically $50,000-$150,000+

• Increased complication risk vs. primary surgery

• Possible permanent disability from revision

• Permanent loss of hip function

• Soft tissue destruction not fully recoverable

• Bone loss not fully recoverable

• Permanent disability in some cases

What is the procedural history of Stryker hip implant litigation?

Stryker hip litigation proceeded through two parallel federal MDLs: MDL 2441 in Minnesota (Rejuvenate/ABG II, established June 2013) and MDL 2768 in Massachusetts (LFIT V40, established April 2017). The Rejuvenate/ABG II cases settled for approximately $1.4 billion in November 2014. The LFIT V40 cases settled for $75 million in late 2021. Both MDLs remain technically open.

Rejuvenate and ABG II track (MDL 2441)

2008-2010. Stryker launches Rejuvenate Modular-Neck Hip System.

2009-2012. Increasing reports of modular junction failures.

July 6, 2012. Stryker voluntarily recalls Rejuvenate and ABG II Modular Hip Systems. Initial reports of corrosion and fretting at modular neck junctions.

June 12, 2013. Judicial Panel on Multidistrict Litigation establishes MDL 2441 (In re: Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation) in District of Minnesota.

Bergen County, New Jersey state court litigation. parallel state court action.

November 3, 2014. Stryker announces global settlement program for eligible U.S. patients:

• Eligibility: Revision surgery before November 3, 2014 for reasons related to recall
• Minimum award $300,000 to most victims (largest minimum in hip replacement litigation history)
• Future compensation potential for previously settled cases

2015-2018. settlement processing and individual case resolution.

Current status (January 2026). Approximately 16 cases pending in MDL 2441.

LFIT V40 track (MDL 2768)

2002-2016. Stryker manufactures and markets LFIT V40 Femoral Heads in various sizes.

September 2016. Stryker issues voluntary recall of LFIT Anatomic CoCr V40 Femoral Heads.

April 5, 2017. Judicial Panel on Multidistrict Litigation establishes MDL 2768 (In re: Stryker LFIT V40 Femoral Head Products Liability Litigation) in District of Massachusetts.

New Jersey Multicounty Litigation (MCL 624). parallel state court action in Bergen County.

Late 2018-2019. Active discovery and motion practice.

November-December 2021. Master Settlement Agreement reached:

• 500 plaintiffs / ~2,500 claims
• Stay of discovery entered to facilitate settlement
• "Aiding Private Settlement" order December 2021
• Compensation based on level of harm and components removed
• Eligible: Recalled and unrecalled cobalt chromium V40 heads
• Compatible stems: Accolade TMZF, Accolade 2, Citation, Meridian, Rejuvenate

Current status (January 2026). Approximately 55-62 cases pending in MDL 2768.

How do the Stryker hip implant settlement frameworks work?

The Rejuvenate/ABG II settlement provides a $300,000 minimum base award to most eligible plaintiffs with enhancements for severe injuries, while the LFIT V40 Master Settlement Agreement uses confidential individual case valuations based on harm severity and components removed. Both frameworks require medical record review, independent evaluation, and documented revision surgery.

The Stryker settlements established procedural standards for hip implant litigation:

Rejuvenate/ABG II settlement framework

Base award. $300,000 minimum to most eligible plaintiffs:

• Stryker Rejuvenate or ABG II Modular Hip System recipient

• Revision surgery before November 3, 2014

• Reasons related to the recall (corrosion, fretting, modular junction failure)

• Few reductions from base award

• Strong settlement framework for plaintiffs

How do you evaluate eligibility for remaining Stryker hip implant cases?

Eligibility for remaining Stryker hip implant cases requires verifying the specific Stryker product through surgical records and implant cards, documenting injuries with metal ion blood testing and imaging studies, confirming revision surgery, and analyzing the applicable statute of limitations under the discovery rule. Correct product identification is critical to qualifying for the right MDL or settlement program.

Documenting the Stryker product

• Implant card (if patient received)

• Hospital records identifying specific product and component

• Lot numbers and serial numbers

• Specific product line (Rejuvenate, ABG II, LFIT V40, other)

• Specific stem and head combinations

Statute of limitations analysis

• Limitations begin when patient knew or should have known
• Some patients with delayed discovery have viable cases
• Some 2014 settlement framework participants may have additional rights

How does Stryker hip litigation compare to other medical device mass torts?

Stryker hip litigation is distinctive for operating two parallel federal MDLs for different product lines, achieving a $1.4 billion global settlement with a $300,000 minimum award for Rejuvenate/ABG II cases, and resolving the majority of claims through structured settlement programs. Its dual MDL structure and minimum award baseline set precedents in medical device mass tort resolution.

• TWO parallel MDLs for different product lines
• $1.4 billion global settlement (Rejuvenate/ABG II)
• $300,000 minimum award baseline)
• $75 million LFIT V40 settlement
• Strong settlement framework for similar future device mass torts
• Tritanium Acetabular Shell emerging litigation
• Joint federal MDL + state court consolidation (NJ MCL)

What are the settlement projections for remaining Stryker hip implant cases?

Remaining Rejuvenate/ABG II cases are limited, with the 2014 settlement framework still operating for late-emerging complications or discovery-rule claims. LFIT V40 cases continue under the 2021 settlement framework with individual evaluation.

For current and prospective plaintiffs with documented Stryker hip injuries:

• Remaining cases may receive offers
• Range varies with injury severity
• Some new cases still accepted

Tax implications. Personal injury settlements for physical injuries are tax-free under IRC §104(a)(2). Coordinate with tax counsel for settlements, particularly when other tax debt issues exist or when reasonable cause penalty defenses apply.

What are the strategic considerations for Stryker hip implant plaintiffs?

Plaintiffs should prioritize accurate product identification through surgical records, comprehensive injury documentation including metal ion testing and revision surgery records, timely statute of limitations analysis, and engagement with counsel experienced in Stryker settlement program navigation. Medical necessity should guide revision surgery timing, and plaintiffs should not accept initial settlement offers without thorough evaluation of documented damages.

Identify the specific Stryker product carefully. Critical first step:

Address the statute of limitations carefully. Most cases:

• 2-4 year limitations period
• Some delayed discovery cases viable
• Some 2014 settlement participants may have additional rights

Consider future complications. Per Rejuvenate/ABG II settlement:

Address the Tritanium Acetabular Shell separately. Different framework:

Coordinate with treating providers. Orthopedic surgeons, pain management specialists, and other treating physicians are important witnesses.

Address related tax planning. Personal injury settlements for physical injuries are tax-free. Component allocation (physical injury vs. emotional distress) affects tax treatment.

Watch the wrongful death framework. Some severe metallosis cases:

• Loss of function post-implant
• Inability to return to work

Coordinate medical and legal timelines. Some patients face decision between:

Medical necessity should dominate, but legal counsel can advise on timing implications.

• New Jersey MCL 624 (parallel state court)
• May benefit some specific case profiles

Address the medical monitoring component. Even after revision:

Don't accept inadequate settlement offers without thorough evaluation. Many cases:

• Injury justifies more than initial offers
• Negotiate based on documented damages
• Consider litigation if settlement insufficient
• Multiple revision cases may justify substantially higher amounts

For affected patients with documented Stryker hip implant injuries, the framework provides substantial compensation through established settlement programs that have resolved the majority of cases. The Rejuvenate/ABG II $1.4 billion settlement with $300,000 minimum awards remains one of the largest minimum settlement provisions in hip replacement litigation history, and the LFIT V40 $75 million settlement provided case evaluation framework. Both MDLs technically remain open with some new case acceptance, particularly for the LFIT V40 product line. The emerging Tritanium Acetabular Shell litigation represents the next phase of Stryker hip implant mass tort framework. The work for affected patients is in comprehensive product identification through surgical records, thorough injury documentation including metal ion testing and revision surgery records, engagement with experienced Stryker hip counsel familiar with settlement program navigation, coordination of medical and legal timelines, and careful consideration of statute of limitations issues. For patients with documented injuries meeting eligibility requirements, the established settlement frameworks provide meaningful compensation reflecting the serious nature of metal-on-metal hip implant failure and the medical, surgical, and lifestyle consequences for affected patients.